Abstract
In type 2 diabetes (T2D) glucagon-like peptide-1 receptor agonist use has been associated with blood pressure (BP) reduction and heart rate (HR) acceleration. We studied the effect of 26-wk exenatide (EXE) vs. insulin glargine (IG) on BP and HR and metabolic correlates during cardiopulmonary exercise testing (CPET) in T2D patients with cardiac compromise.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
